Pacific Biosciences (PACB) saw its stock soar 8.04% on Tuesday's trading session, driven by positive analyst ratings and price target updates.
Stephens & Co. maintained a $2.50 price target on PACB, expressing confidence in the company's prospects. Meanwhile, Morgan Stanley reiterated a "Hold" rating on the stock, setting a $2.00 price target.
The updates from these analysts reflect optimism surrounding Pacific Biosciences' future performance, boosting investor sentiment and driving the stock's significant upward movement during Tuesday's trading.